According to researchers, Breast Cancer Patients with HER-2 Positive tumor who do not respond well to Herceptin alone could benefit with a combination of drug Herceptin and one or more P13K-inhibiting agents.
The research team at the University of Texas M.D. Anderson Cancer Center in Houston is due to conduct anther trial, after having successfully tested it on mice. The second stage of the trial, will involve severe cancer cases where the disease has advanced in spite of Herceptin Treatment in Her2 positive patients.Study author Dr. Dihua Yu, a professor in the department of surgical oncology said 'More than half of patients with HER2-positive tumors don't respond to Herceptin as a single agent, and our research has shown us why that is and what might be done to help these patients. If this drug cocktail shows benefit, we hope to be able to identify those patients who won't respond to Herceptin before they start the treatment, and offer them a new and beneficial drug combination. Patients who don't respond to Herceptin have worrisome outcomes, so we hope this strategy will help them.'
There is ample indication, supported by successful outcomes of previous research, which has provided the impetus to a combination treatment for aggressive breast cancers.
